Your browser doesn't support javascript.
loading
Generics versus brand-named drugs for glaucoma: the debate continues.
Bhartiya, Shibal; Dhingra, Deepika.
Afiliación
  • Bhartiya S; Glaucoma Services, Fortis Memorial Research Institute, Gurugram, Haryana, India.
  • Dhingra D; Shah Satnam Ji Speciality Hospitals, Sirsa, Haryana, India.
Rom J Ophthalmol ; 64(3): 239-244, 2020.
Article en En | MEDLINE | ID: mdl-33367157
There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the market with a patent, whereas branded generic drugs are produced by a different company once the patent of innovator company expires. Given that glaucoma is a chronic, largely asymptomatic disease, the choice of drugs is extremely important: the duration of medication is often lifelong, and the cost of drugs, side effects and efficacy affect compliance and adherence to therapy. This review is a brief overview of the available brand name and branded generic drugs for the management of glaucoma, in terms of efficacy and side effect profiles. It also aimed to guide rational and pragmatic drug choices in different clinical scenarios.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glaucoma / Medicamentos Genéricos / Antihipertensivos Límite: Humans Idioma: En Revista: Rom J Ophthalmol Año: 2020 Tipo del documento: Article País de afiliación: India Pais de publicación: Rumanía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glaucoma / Medicamentos Genéricos / Antihipertensivos Límite: Humans Idioma: En Revista: Rom J Ophthalmol Año: 2020 Tipo del documento: Article País de afiliación: India Pais de publicación: Rumanía